Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Net Sales by Business
Clinical Diagnostics$363.6M-14.5%$425.3M+8.7%$391.2M+0.6%$388.8M+9.0%$356.8M-9.1%
Life Science$228.5M-14.7%$267.9M+2.3%$261.8M-0.4%$262.8M+15.0%$228.6M-16.9%
Net Sales by Geography
Americas$45.1M+0.9%$44.7M+12.3%$39.8M-3.2%$41.1M+3.3%$39.8M-3.6%
Asia Pacific$110.4M-31.8%$161.8M+33.7%$121M-4.3%$126.4M+21.4%$104.1M-28.9%
Europe$206.8M-14.8%$242.6M+9.2%$222.2M+2.3%$217.2M+8.7%$199.8M-9.9%
UNITED STATES$229.8M-5.9%$244.1M-9.6%$270M+1.2%$266.9M+10.4%$241.7M-6.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How does Bio-Rad Laboratories, Inc. break its business down?
Bio-Rad Laboratories, Inc. (BIO.B) reports net sales by business across 3 parts — All Other Segments, Clinical Diagnostics and Life Science. Each is extracted from the segment footnotes and tracked over time.
Where does Bio-Rad Laboratories, Inc.'s segment data come from?
Segment breakdowns are pulled from the segment footnotes in Bio-Rad Laboratories, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.